Date | Name | Symbol | Type | Security | Shares | Price | Value | Ownership | Reported |
06/07/2023 | Cerevel Therapeutics Holdings, Inc. | CERE | Grant | Common Stock | 3.3k | $0.00 | $0 | | 06/07/2023 |
06/07/2023 | Cerevel Therapeutics Holdings, Inc. | CERE | Grant | Stock Option (Right to Buy) | 13.8k | $32.60 | $449.2k | | 06/07/2023 |
11/03/2022 | Ginkgo Bioworks Holdings, Inc. | | Sale | Class A Common Stock | 171.5k | $2.56 | $438.9k | | 11/03/2022 |
06/14/2022 | Cerevel Therapeutics Holdings, Inc. | CERE | Grant | Stock Option (Right to Buy) | 23.5k | $24.35 | $571.2k | | 06/14/2022 |
06/10/2022 | Ginkgo Bioworks Holdings, Inc. | | Grant | Stock Option | 108.5k | $2.82 | $306k | | 06/10/2022 |
06/10/2022 | Ginkgo Bioworks Holdings, Inc. | | Grant | Class A Common Stock | 70.9k | $0.00 | $0 | | 06/10/2022 |
05/11/2022 | Quantum-Si Inc | | Grant | Stock Option (right to buy) | 59.9k | $3.06 | $183.2k | | 05/11/2022 |
03/11/2022 | Ginkgo Bioworks Holdings, Inc. | | Grant | Class A Common Stock | 1.7M | $0.00 | $0 | | 03/11/2022 |
09/24/2021 | Cerevel Therapeutics Holdings, Inc. | CERE | Exercise | Restricted Stock Units | 14.3k | $0.00 | $0 | | 09/24/2021 |
09/16/2021 | Ginkgo Bioworks Holdings, Inc. | | Grant | Class A Common Stock | 375k | $0.00 | $0 | | 09/16/2021 |
09/16/2021 | Ginkgo Bioworks Holdings, Inc. | | Grant | Class A Common Stock | 5.8M | $0.00 | $0 | By Novalis LifeSciences Investments I, L.P. | 09/16/2021 |
06/11/2021 | Quantum-Si Inc | | Grant | Class A Common Stock | 20.5k | $0.00 | $0 | | 06/10/2021 |
06/10/2021 | Quantum-Si Inc | | Grant | Class A Common Stock | 500k | $10.00 | $5M | By Novalis Lifesciences Investments I, LP | 06/10/2021 |
06/10/2021 | Quantum-Si Inc | | Grant | Class A Common Stock | 150k | $0.00 | $0 | | 06/10/2021 |
06/10/2021 | Cerevel Therapeutics Holdings, Inc. | CERE | Grant | Stock Option (Right to Buy) | 58k | $13.93 | $808k | | 06/10/2021 |
06/07/2021 | Quanterix Corp | QTRX | Sale | Common Stock | 4.4k | $55.58 | $242.3k | | 01/11/2021 |
06/07/2021 | Quanterix Corp | QTRX | Sale | Common Stock | 4.7k | $56.24 | $263.8k | | 01/11/2021 |
06/07/2021 | Quanterix Corp | QTRX | Exercise | Stock Option (Right to Buy) | 4.7k | $23.12 | $109.4k | | 01/11/2021 |
06/04/2021 | Quanterix Corp | QTRX | Exercise | Stock Option (Right to Buy) | 3.2k | $23.12 | $73.2k | | 01/11/2021 |
06/04/2021 | Quanterix Corp | QTRX | Exercise | Stock Option (right to buy) | 2k | $8.16 | $15.9k | | 01/11/2021 |
06/04/2021 | Quanterix Corp | QTRX | Sale | Common Stock | 7.6k | $55.05 | $418.9k | | 01/11/2021 |
01/11/2021 | Quanterix Corp | QTRX | Exercise | Stock Option (right to buy) | 29.2k | $8.16 | $238k | | 01/11/2021 |
01/11/2021 | Quanterix Corp | QTRX | Exercise | Stock Option (Right to Buy) | 7.9k | $14.80 | $116.9k | | 01/11/2021 |
01/11/2021 | Quanterix Corp | QTRX | Exercise | Stock Option (Right to Buy) | 7.9k | $18.24 | $144.1k | | 01/11/2021 |
01/11/2021 | Quanterix Corp | QTRX | Sale | Common Stock | 8.2k | $51.08 | $418.8k | | 01/11/2021 |
01/11/2021 | Quanterix Corp | QTRX | Sale | Common Stock | 4.4k | $50.38 | $221.7k | | 01/11/2021 |
01/11/2021 | Quanterix Corp | QTRX | Sale | Common Stock | 2.3k | $49.16 | $114.7k | | 01/11/2021 |
01/11/2021 | Quanterix Corp | QTRX | Sale | Common Stock | 22.8k | $47.87 | $1.1M | | 01/11/2021 |
01/11/2021 | Quanterix Corp | QTRX | Sale | Common Stock | 7.2k | $47.17 | $339.6k | | 01/11/2021 |
01/04/2021 | Quanterix Corp | QTRX | Grant | Common Stock | 2.3k | $0.00 | $0 | | 01/04/2021 |
01/04/2021 | Quanterix Corp | QTRX | Grant | Stock Option (Right to Buy) | 7.9k | $44.10 | $348.4k | | 01/04/2021 |
08/07/2020 | Quanterix Corp | QTRX | Sale | Common Stock | 27.6k | $32.49 | $897.3k | Held by Novalis LifeSciences Investments I, L.P. | 08/07/2020 |
01/02/2020 | Quanterix Corp | QTRX | Grant | Common Stock | 2.3k | $0.00 | $0 | | 01/02/2020 |
01/02/2020 | Quanterix Corp | QTRX | Grant | Stock Option (Right to Buy) | 7.9k | $23.12 | $182.6k | | 01/02/2020 |
08/20/2019 | Quanterix Corp | QTRX | Sale | Common Stock | 59.2k | $12.92 | $764.5k | | 08/20/2019 |
|